MedTrace Logo

Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

NCT06003881 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2025-11-10

No results posted yet for this study

Summary

The program is to provide access to an experimental drug called pozelimab and to document the long-term safety of pozelimab in patients with Protein-Losing Enteropathy (PLE). CD55-deficient PLE/CHAPLE disease is a rare inherited disease of the immune system. This can be a life-threatening condition that is usually found when patients are children.

Conditions

  • CD55-Deficient Protein-Losing Enteropathy

Interventions

DRUG

Pozelimab

Subcutaneous (SC) administration

Sponsors & Collaborators

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06003881 on ClinicalTrials.gov